CRISPR-Cas immunity is repressed by the LysR-type transcriptional regulator PigU
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkad1165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Leah M Smith und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Otago, PO Box 56, Dunedin 9054, New Zealand. Hauptthemen laut MEDLINE: Bacteriophages, CRISPR-Cas Systems, Serratia, Bacterial Proteins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Society of New Zealand, University of Otago Doctoral Scholarships.
Abstract (Originalsprache)
Bacteria protect themselves from infection by bacteriophages (phages) using different defence systems, such as CRISPR-Cas. Although CRISPR-Cas provides phage resistance, fitness costs are incurred, such as through autoimmunity. CRISPR-Cas regulation can optimise defence and minimise these costs. We recently developed a genome-wide functional genomics approach (SorTn-seq) for high-throughput discovery of regulators of bacterial gene expression. Here, we applied SorTn-seq to identify loci influencing expression of the two type III-A Serratia CRISPR arrays. Multiple genes affected CRISPR expression, including those involved in outer membrane and lipopolysaccharide synthesis. By comparing loci affecting type III CRISPR arrays and cas operon expression, we identified PigU (LrhA) as a repressor that co-ordinately controls both arrays and cas genes. By repressing type III-A CRISPR-Cas expression, PigU shuts off CRISPR-Cas interference against plasmids and phages. PigU also represses interference and CRISPR adaptation by the type I-F system, which is also present in Serratia. RNA sequencing demonstrated that PigU is a global regulator that controls secondary metabolite production and motility, in addition to CRISPR-Cas immunity. Increased PigU also resulted in elevated expression of three Serratia prophages, indicating their likely induction upon sensing PigU-induced cellular changes. In summary, PigU is a major regulator of CRISPR-Cas immunity in Serratia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Otago, PO Box 56, Dunedin 9054, New Zealand.
- Genetics Otago, University of Otago, PO Box 56, Dunedin 9054, New Zealand.
- Maurice Wilkins Centre for Molecular Biodiscovery, University of Otago, PO Box 56, Dunedin 9054, New Zealand.
- Laboratory of Microbiology, Department of Agrotechnology and Food Sciences, Wageningen University, Dreijenplein 10, 6703 HB Wageningen, The Netherlands.
- Bioprotection Aotearoa, University of Otago, PO Box 56, Dunedin 9054, New Zealand.
ORCID-Profile: Leah M Smith, Peter C Fineran
Förderung
- Royal Society of New Zealand
- University of Otago Doctoral Scholarships
Zitieren
APA
Smith, L. M., Hampton, H. G., Yevstigneyeva, M. S., Mahler, M., Paquet, Z. S. M., & Fineran, P. C. (2024). CRISPR-Cas immunity is repressed by the LysR-type transcriptional regulator PigU. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad1165
Vancouver
Smith LM, Hampton HG, Yevstigneyeva MS, Mahler M, Paquet ZSM, Fineran PC. CRISPR-Cas immunity is repressed by the LysR-type transcriptional regulator PigU. Nucleic Acids Research. 2024. doi:10.1093/nar/gkad1165
BibTeX
@article{Smith2024,
author = {Smith, Leah M and Hampton, Hannah G and Yevstigneyeva, Mariya S and Mahler, Marina and Paquet, Zacharie S M and Fineran, Peter C},
title = {CRISPR-Cas immunity is repressed by the LysR-type transcriptional regulator PigU},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkad1165}
}
EUVIMED